This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.

This study has been completed.
Onze Lieve Vrouw Hospital
Information provided by (Responsible Party):
Dr. Decleer Wim, AZ Jan Palfijn Gent Identifier:
First received: August 23, 2012
Last updated: March 9, 2015
Last verified: March 2015
In this study of endometriosis patients we compare a common treatment of surgical therapy and medical treatment for 3 months (Zoladex) with patients receiving only surgical therapy. In both cases they immediately start In Vitro Fertilization (IVF) treatment.

Condition Intervention Phase
Infertility Endometriosis Drug: Zoladex Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates.

Resource links provided by NLM:

Further study details as provided by Dr. Decleer Wim, AZ Jan Palfijn Gent:

Primary Outcome Measures:
  • Number of Metaphase II Cells (MII) [ Time Frame: 3 weeks ]
    number of MII cells retrieved

Secondary Outcome Measures:
  • Pregnancy Rate [ Time Frame: 12 weeks ]
    The number of ongoing pregnancies obtained which still is the most important issue for the patients.

  • Good Embryo Quality [ Time Frame: 3 days after oocyte retrieval ]
    The development of the embryo at the time of transfer on day 3. Good quality is defined by more than 7 cells and less then 20% fragmentation on day 3.

  • Number of Pro Nuclear Cell (2PN) [ Time Frame: 1 day after oocyte retrieval ]
    number of 2PN

  • Number of Cryopreserved Embryos [ Time Frame: 1 week after oocyte retrieval ]
    number of blastocytes that can be cryopreserved

  • Total Follicle Stimulating Hormone (FSH) Dose [ Time Frame: 3 weeks ]
    total dose of FSH needed at the end of stimulation

Other Outcome Measures:
  • Number of Days of Stimulation [ Time Frame: 3 weeks ]
    number of days needed before follicles in the ovary are mature for oocyte retrieval

Enrollment: 120
Study Start Date: March 2012
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Zoladex
After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
Drug: Zoladex
after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
No Intervention: vaporization only
Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.


Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • laparoscopical vaporization of endometriosis
  • 1,2, 3e IVF cycle
  • endometriosis stage I and II
  • younger than 38 years

Exclusion Criteria:

  • endometriosis cysts
  • uterine pathology
  • endocrinological diseases and problems
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01682642

AZ Jan Palfijn
Gent, Oost-vlaanderen, Belgium, 9000
Sponsors and Collaborators
AZ Jan Palfijn Gent
Onze Lieve Vrouw Hospital
Principal Investigator: Wim Decleer, gynecologist Fertility Center AZ Jan Palfijn Gent
Study Chair: Paul Devroey, Professor Fertility Center AZ Jan Palfijn Gent
  More Information

Responsible Party: Dr. Decleer Wim, gynecologist, AZ Jan Palfijn Gent Identifier: NCT01682642     History of Changes
Other Study ID Numbers: 2012-000784-25
Study First Received: August 23, 2012
Results First Received: February 5, 2015
Last Updated: March 9, 2015

Keywords provided by Dr. Decleer Wim, AZ Jan Palfijn Gent:
In Vitro Fertilization (IVF)/Intra Cytoplastic Sperm Injection (ICSI)
peritoneal implants
embryo quality

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on September 21, 2017